Date: Nov 9, 2015

German pilot demonstrated that in a ‘real world’ clinical setting, targeted treatment guided by a test for EPA can have a significant impact on clinical outcomes at 12 weeks, at no additional material cost to the clinic

The pilot carried out across 9 wound care clinics in Germany involved the testing of 107 newly referred chronic wounds for EPA using WOUNDCHEK™ Protease Status as part of the clinician’s assessment of the wound and treatment decision making. 

Read More

At 12 weeks the proportion of wounds healed / healing in the test group (52%, 56/107) was significantly higher than that of the comparator group (36%, 32/90) (p=0.034) and a total material savings of €2,044 per EPA wound identified was documented.